about
Comparison of serologic assays for detection of antibodies against human herpesvirus 8.Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine.Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles.Microbial factories for recombinant pharmaceuticalsBiomedical applications of distally controlled magnetic nanoparticles.Engineered biological entities for drug delivery and gene therapy protein nanoparticles.Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.Post-production protein stability: trouble beyond the cell factory.Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies.Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells.In vivo architectonic stability of fully de novo designed protein-only nanoparticles.Sheltering DNA in self-organizing, protein-only nano-shells as artificial viruses for gene delivery.Comparison of serologic responses between Kaposi's sarcoma-positive and -negative men who were seropositive for both human herpesvirus 8 and human immunodeficiency virus.Improving the binding capacity of Ni2+ decorated porous magnetic silica spheres for histidine-rich protein separation.Design and characterization of Ni2+ and Co2+ decorated Porous Magnetic Silica spheres synthesized by hydrothermal-assisted modified-Stöber method for His-tagged proteins separation.Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies.Bacterial inclusion bodies: making gold from wasteReversible activation of a cryptic cleavage site within E. coli β-galactosidase in β-galactosidase fusion proteinsThe position of the heterologous domain can influence the solubility and proteolysis of β-galactosidase fusion proteins in E. coliMitomycin C stimulates thermally induced recombinant gene expression in Escherichia coli MC strainsPlasmid maintenance in Escherichia coli recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteinsThe expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in Escherichia coliTolerance of Escherichia coli beta-galactosidase C-terminus to different-sized fusionsLatest Advances in the Development of Eukaryotic Vaults as Targeted Drug Delivery SystemsThe expression of recombinant genes from bacteriophage lambda strong promoters triggers the SOS response in escherichia coli
P50
Q33999426-64AB0D2D-4CBB-472A-A355-75ACE1679466Q35919949-D7944BC9-A9DF-4D62-8CCC-943DDB025BE6Q36176102-0EC8F0AC-9E46-4457-95A9-8851EF9E7850Q37160231-FA59ADAD-C02D-4CA8-9195-19DF0BE89D82Q37535270-0AFD5033-837A-4F19-8698-B4F1F4F92C03Q37957323-48C7A9A9-7D61-4A61-ADFA-12EA235D0C70Q38044091-1EA146EF-41E4-4ABA-AFE3-C43A7B37A415Q38264351-947444A7-D473-46A9-9C5A-59A03860C8D5Q39381101-D8CA5D78-59D7-44F7-8FE0-9DDB07FD5C7EQ39535178-62ECF1A7-B282-4B9A-A244-8E38A22E26AAQ42226433-E2449CD5-37A6-4763-89FB-64F7705A8A28Q42253497-FBEC3207-0EC2-44E7-A50B-0E6D546ADDF7Q45596372-6115BD5B-7716-4911-B1F2-2A5B863921A6Q50490121-26751BDE-E39D-45C3-B1A9-7DB506C720FDQ50510109-B9F19669-1EF0-4831-9069-8865197DBAEBQ54321575-CB59C937-C98B-430F-90F9-729DCA3580DCQ59201800-DDD3A970-30F6-4211-B86C-F29A08E16595Q59201870-1C2ECA78-B018-4771-860B-EA0319846F9DQ59201873-B7D736A1-7096-4A09-BAF3-D8758790C22EQ59201877-D054926A-11E0-4912-BF40-A24E3C76F24AQ74660064-00939171-2CEA-4444-9B32-5C69109BF047Q74660631-8E9B2BD9-77BB-4052-88C3-AC1110A060DCQ78031429-68B5A1E6-993E-4212-A742-7E27603A3CF0Q91517853-5382B06A-F744-44EB-A570-BA2B92E51446Q95305668-DF83081B-0768-490C-9AC0-776586FA5A49
P50
description
researcher
@en
wetenschapper
@nl
name
J L Corchero
@en
J L Corchero
@nl
type
label
J L Corchero
@en
J L Corchero
@nl
prefLabel
J L Corchero
@en
J L Corchero
@nl
P106
P31
P496
0000-0002-6109-144X